US 12,377,100 B2
Toll like receptor modulator compounds
Evangelos Aktoudianakis, Redwood City, CA (US); Gregory Chin, San Francisco, CA (US); Richard L. Mackman, Millbrae, CA (US); Samuel E. Metobo, Newark, CA (US); Michael R. Mish, Foster City, CA (US); Hyung-Jung Pyun, Fremont, CA (US); and Jeff Zablocki, Los Altos, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by GILEAD SCIENCES, INC., Foster City, CA (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,563.
Application 17/540,563 is a continuation of application No. 16/254,333, filed on Jan. 22, 2019, abandoned.
Application 16/254,333 is a continuation of application No. 15/496,283, filed on Apr. 25, 2017, granted, now 10,285,990, issued on May 14, 2019.
Application 15/496,283 is a continuation of application No. 15/059,070, filed on Mar. 2, 2016, granted, now 9,670,205, issued on Jun. 6, 2017.
Claims priority of provisional application 62/250,403, filed on Nov. 3, 2015.
Claims priority of provisional application 62/128,397, filed on Mar. 4, 2015.
Prior Publication US 2022/0218709 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/517 (2006.01); C07D 239/84 (2006.01); C07D 401/04 (2006.01)
CPC A61K 31/517 (2013.01) [C07D 239/84 (2013.01); C07D 401/04 (2013.01); C07D 471/04 (2013.01)] 5 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, of Formula (IVa)

OG Complex Work Unit Chemistry
R1 is hydrogen;
R2 is hydrogen, methyl, fluoro or chloro;
R3 is hydrogen or methyl; and
the moiety

OG Complex Work Unit Chemistry